Pharmacovigilance and Pharmacoeconomics of cancer chemotherapy medications in a tertiary care hospital.
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 140
- 试验地点
- 1
- 主要终点
- Adverse Drug Reaction, Drug Interaction, cost effectiveness, cost utility and budget impact of chemotherapeutic medication
研究概览
简要总结
Pharmacoeconomics and pharmacovigilance are not separate departments in a tertiary care hospital. Pharmacoeconomic analyses are directly informed by the frequency and severity of adverse drug reactions (ADRs) data collected through pharmacovigilance. A medication that frequently and severely causes side effects, for example, may result in longer hospital stays and the need for additional treatments, raising the overall cost of care.
Tertiary care hospitals can make well-informed decisions about which cancer chemotherapeutic drugs to add to their formularies by combining these two domains, guaranteeing a balance between treatment effectiveness, patient safety, and financial viability.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18.00 Year(s) 至 85.00 Year(s)（—）
- 性别
- All
入选标准
- •Cancer patients on chemotherapy treatment
- •Patients with solid tumors or hematological malignancy.
排除标准
- •Patient not consenting for study
- •Patients on Radiation Therapy.
结局指标
主要结局
Adverse Drug Reaction, Drug Interaction, cost effectiveness, cost utility and budget impact of chemotherapeutic medication
时间窗: Assessment will be done at two weeks
次要结局
未报告次要终点
研究者
Dr Rohan Motwani
Datta Meghe Institute of Higher Education and Research